NCT07220135View on ClinicalTrials.gov

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 14, 2025

Primary Completion Date

November 14, 2027

Study Completion Date

May 14, 2031

Conditions
Breast Cancer
Interventions
DRUG

Carboplatin

All of the treatment being received by the study participants during the course of the study is standard of care.

DRUG

Docetaxel

All of the treatment being received by the study participants during the course of the study is standard of care.

DRUG

Trastuzumab (or biosimilar)

All of the treatment being received by the study participants during the course of the study is standard of care.

DRUG

Pertuzumab (or biosimilar)

All of the treatment being received by the study participants during the course of the study is standard of care.

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER